Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis
We assessed the cardiovascular safety of long-term direct-acting oral anticoagulant (DOAC) treatment. A search of the medical literature was performed from inception until May 31, 2019. Inclusion criteria were (1) randomized trial that assessed the clinical efficacy and/or safety of 1 or more DOAC,...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2019
|
| Sorozat: | ANGIOLOGY
In press |
| doi: | 10.1177/0003319719874255 |
| mtmt: | 30810276 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/16884 |
| LEADER | 02568nab a2200361 i 4500 | ||
|---|---|---|---|
| 001 | publ16884 | ||
| 005 | 20191001130958.0 | ||
| 008 | 191001s2019 hu o 0|| zxx d | ||
| 022 | |a 0003-3197 | ||
| 024 | 7 | |a 10.1177/0003319719874255 |2 doi | |
| 024 | 7 | |a 30810276 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Kupó Péter | |
| 245 | 1 | 0 | |a Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis |h [elektronikus dokumentum] / |c Kupó Péter |
| 260 | |c 2019 | ||
| 490 | 0 | |a ANGIOLOGY |v In press | |
| 520 | 3 | |a We assessed the cardiovascular safety of long-term direct-acting oral anticoagulant (DOAC) treatment. A search of the medical literature was performed from inception until May 31, 2019. Inclusion criteria were (1) randomized trial that assessed the clinical efficacy and/or safety of 1 or more DOAC, (2) control group including oral anticoagulation and/or antiplatelet and/or placebo treatment, and (3) the incidence of acute coronary syndrome during follow-up was reported. Fixed-effect and random-effects models were applied. The analyzed outcomes were myocardial infarction (MI), major bleeding, and mortality. Twenty-eight randomized clinical trials (196 761 patients) were included. Rivaroxaban was associated with a 21% reduction in the relative risk of MI when compared to placebo (relative risk [RR]: 0.79 [95% credible interval, CrI: 0.65-0.94]) and a 31% reduction (RR: 0.70 [95% CrI: 0.53-0.89]) when compared to dabigatran. Apixaban resulted in 24% (RR: 0.76 [95% CrI: 0.58-0.99]) and vitamin K antagonists anticoagulation resulted in 19% (RR: 0.81 [95% CrI: 0.65-0.98]) risk reduction compared to dabigatran. The computed probability of being the first best choice of treatment was 61.8% for rivaroxaban. Cardiovascular safety shows considerable heterogeneity among oral anticoagulants. Treatment with rivaroxaban is associated with reduced rate of MI. | |
| 700 | 0 | 1 | |a Szakács Zsolt |e aut |
| 700 | 0 | 2 | |a Varjú-Solymár Margit |e aut |
| 700 | 0 | 2 | |a Habon Tamás |e aut |
| 700 | 0 | 2 | |a Czopf László |e aut |
| 700 | 0 | 2 | |a Hategan Lídia |e aut |
| 700 | 0 | 2 | |a Csányi Beáta |e aut |
| 700 | 0 | 2 | |a Borbás János |e aut |
| 700 | 0 | 2 | |a Tringer Annamária |e aut |
| 700 | 0 | 2 | |a Varga Gábor |e aut |
| 700 | 0 | 2 | |a Balaskó Márta |e aut |
| 700 | 0 | 2 | |a Sepp Róbert |e aut |
| 700 | 0 | 2 | |a Hegyi Péter |e aut |
| 700 | 0 | 2 | |a Bálint Alexandra |e aut |
| 700 | 0 | 2 | |a Komócsi András |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/16884/1/2019_Direct_Anticoagulants_Angiology.pdf |z Dokumentum-elérés |